Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind Randomised 2-Arm, 2-Period Crossover Study to Access the Similarity of Safety and Pharmacokinetics of JHL1922 and Pulmozyme® After Single and Repeated Administration in Healthy Subjects

Trial Profile

A Double-Blind Randomised 2-Arm, 2-Period Crossover Study to Access the Similarity of Safety and Pharmacokinetics of JHL1922 and Pulmozyme® After Single and Repeated Administration in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Dornase alfa (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors JHL Biotech
  • Most Recent Events

    • 01 Mar 2018 According to a JHL Biotech media release, the Dutch Healthcare Authority has approved the Clinical Trial Application (CTA) for JHL1922 facilitating initiation of this trial in Netherlands in March 2018.
    • 22 Feb 2018 Status changed from planning to recruiting, as reported in a JHL Biotech media release.
    • 26 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top